Regorafenib

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had 2 US approvals for advanced cancers.

Product Description:

1) Product Name:  Supply regorafenib/(BAY 73-4506) CAS:755037-03-7

2) Specification: 99% 

3) Testing Method: HPLC

4) Appearance: White to off-white powder

Specifications

Items	Specifications	Results
Appearance	White to whitish crystal powder	Conforms
Loss on drying	NMT 0.5%	0.33%
Residue on ignition	NMT 0.1%	Conforms
Heavy metal	NMT 20ppm	Conforms
Assay (HPLC)	NLT 99.5%	99.77%
Related substances	NMT 0.5%	0.23%
Single impurity	NMT 0.1%	0.07%
Conclusion: Complies to the Enterprise standard

Packaging & Shipping:

25kg carton drum (32cm*58cm)or 1kg foil bag (10cm*15cm) or by request of clients

Transit could be DHL,UPS,TNT,EMS,Fedex,and so on.

For mass orders, it will be delivered by air or sea.

Depending on your location, please allow 1-5 business days for your order to arrive.

For small order, please expect 3-7 days by UPS DHL EMS.

For mass order, please allow 5-8 days by Air, 15-30 days by Sea.

my contact infomation is:
Email: bettyapi1989@yahoo.com 
bettyapi1989@163.com
Skype: bettyapi1989
whatapp: 008613739707029


Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body